Maraviroc + Truvada
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Jan 1, 2018 → Mar 16, 2021
NCT ID
NCT04965662About Maraviroc + Truvada
Maraviroc + Truvada is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04965662. Target conditions include HIV-1-infection.
What happened to similar drugs?
11 of 18 similar drugs in HIV-1-infection were approved
Approved (11) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04965662 | Approved | Completed |
Competing Products
20 competing products in HIV-1-infection